Abstract
A monoclonal antibody detecting amniotrophoblastic antigen 5T4 has shown reactivity against various neoplastic cell lines and tumour specimens but with a relatively restricted normal tissue expression. This antibody has been investigated as a potential indicator of premalignant changes identified as cervical intra-epithelial neoplasia and malignant cervical lesions using immunohistochemistry on frozen tissue biopsies. The basal cells of normal cervical stratified epithelium exhibited faint staining, but a general increase in intensity and extent of specific labeling of this tissue was seen from the first premalignant stage through to carcinoma. In most cases, this was in accordance with the distribution of dysplastic cells, and was accompanied by increased specific staining of the stromal tissue. All invasive squamous carcinomas of the cervix were 5T4 antigen positive. Common inflammatory non-malignant diseases did show a certain degree of epithelial and stromal reactivity. These results, showing 5T4 reactivity with neoplastic and pre-neoplastic lesions, may provide a quantitative basis for its potential use as a tumour marker in the immunochemical detection on immunoassay of cervical cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, H., Roberts, G., Hole, N. et al. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer 61, 96–100 (1990). https://doi.org/10.1038/bjc.1990.21
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.21
This article is cited by
-
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
Current Oncology Reports (2014)
-
Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins
Cancer Gene Therapy (2002)